Effects of the antioxidant drug tempol on renal oxygenation in mice with reduced renal mass

American Journal of Physiology - Renal Physiology

Volumn 303, Issue 1, 2012, Pages

  Lai, En Yin ^a   Luo, Zaiming ^a   Onozato, Maristela L ^a   Rudolph, Earl H ^a   Solis, Glenn ^a   Jose, Pedro A ^c   Wellstein, Anton ^b   Aslam, Shakil ^a   Quinn, Mark T ^f   Griendling, Kathy ^d   Le, Thu ^e   Li, Ping ^a   Palm, Fredrik ^a   Welch, William J ^a   Wilcox, Christopher S ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF VIRGINIA   (United States)

^f MONTANA STATE UNIVERSITY   (United States)

Author keywords

Chronic kidney disease; Hypertension; Oxidative stress; Reactive oxygen species; Uncoupling protein

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; GLUTATHIONE PEROXIDASE 1; GLUTATHIONE TRANSFERASE; PROTEIN P22; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; TEMPOL; TRANSCRIPTION FACTOR NRF2; TRANSFORMING GROWTH FACTOR BETA; UNCOUPLING PROTEIN 2;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DIET; DRUG EFFECT; ENZYME ACTIVATION; GLOMERULUS; HYPOXIA; IMMUNOHISTOCHEMISTRY; KIDNEY DEVELOPMENT; KIDNEY FIBROSIS; KIDNEY SIZE; KIDNEY TUBULE; MALE; MOUSE; NONHUMAN; OXYGENATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL OXYGENATION; SALT INTAKE; SODIUM TRANSPORT; TUBULOINTERSTITIAL FIBROSIS; UPREGULATION; URINARY EXCRETION;

EID: 84863320549     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00005.2012     Document Type: Article

References (73)

1. Baylis C. Nitric oxide deficiency in chronic kidney disease. Am J Physiol Renal Physiol 294: F1-F9, 2008.
2. Baylis C. Arginine, arginine analogs and nitric oxide production in chronic kidney disease. Nat Clin Pract Nephrol 2: 209-220, 2006.
3. Bidani AK, Mitchell KD, Schwartz MM, Navar LG, Lewis EJ. Absence of glomerular injury or nephron loss in a normotensive rat remnant kidney model. Kidney Int 38: 28-38, 1990.
4. Bondi CD, Manickam N, Lee DY, Block K, Gorin Y, Abboud HE, Barnes JL. NAD(P)H oxidase mediates TGF-beta1-induced activation of kidney myofibroblasts. J Am Soc Nephrol 21: 93-102, 2010.
5. Chanas SA, Jiang Q, McMahon M, McWalter GK, McLellan LI, Elcombe CR, Henderson CJ, Wolf CR, Moffat GJ, Itoh K, Yamamoto M, Hayes JD. Loss of the Nrf2 transcription factor causes a marked reduction in constitutive and inducible expression of the glutathione S-transferase Gsta1, Gsta2, Gstm1, Gstm2, Gstm3 and Gstm4 genes in the livers of male and female mice. Biochem J 365: 405-416, 2002.
6. Collins P, Jones C, Choudhury S, Damelin L, Hodgson H. Increased expression of uncoupling protein 2 in HepG2 cells attenuates oxidative damage and apoptosis. Liver Int 25: 880-887, 2005.
7. Crestani B, Besnard V, Boczkowski J. Signalling pathways from NADPH oxidase-4 to idiopathic pulmonary fibrosis. Int J Biochem Cell Biol 43: 1086-1089, 2011.
8. Deen WM, Maddox DA, Robertson CR, Brenner BM. Dynamics of glomerular ultrafiltration in the rat. VII. Response to reduced renal mass. Am J Physiol 227: 556-562, 1974.
9. Deng A, Munger KA, Valdivielso JM, Satriano J, Lortie M, Blantz RC, Thomson SC. Increased expression of ornithine decarboxylase in distal tubules of early diabetic rat kidneys: are polyamines paracrine hypertrophic factors? Diabetes 52: 1235-1239, 2003.
10. Deng A, Tang T, Singh P, Wang C, Satriano J, Thomson SC, Blantz RC. Regulation of oxygen utilization by angiotensin II in chronic kidney disease. Kidney Int 75: 197-204, 2009.
11. DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, Mangal D, Yu KH, Yeo CJ, Calhoun ES, Scrimieri F, Winter JM, Hruban RH, Iacobuzio-Donahue C, Kern SE, Blair IA, Tuveson DA. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475: 106-109, 2011.
12. Djamali A, Vidyasagar A, Yagci G, Huang LJ, Reese S. Mycophenolic acid may delay allograft fibrosis by inhibiting transforming growth factor-beta1-induced activation of Nox-2 through the nuclear factor-kappaB pathway. Transplantation 90: 387-393, 2010.
13. Echtay KS, Roussel D, St-Pierre J, Jekabsons MB, Cadenas S, Stuart JA, Harper JA, Roebuck SJ, Morrison A, Pickering S, Clapham JC, Brand MD. Superoxide activates mitochondrial uncoupling proteins. Nature 415: 96-99, 2002.
14. Essop MF, Razeghi P, McLeod C, Young ME, Taegtmeyer H, Sack MN. Hypoxia-induced decrease of UCP3 gene expression in rat heart parallels metabolic gene switching but fails to affect mitochondrial respiratory coupling. Biochem Biophys Res Commun 314: 561-564, 2004.
15. Fine LG, Bandyopadhay D, Norman JT. Is there a common mechanism for the progression of different types of renal diseases other than proteinuria? Towards the unifying theme of chronic hypoxia. Kidney Int 57: S22-S26, 2000.
16. Friederich M, Fasching A, Hansell P, Nordquist L, Palm F. Diabetesinduced up-regulation of uncoupling protein-2 results in increased mitochondrial uncoupling in kidney proximal tubular cells. Biochim Biophys Acta 1777: 935-940, 2008.
17. Friederich M, Nordquist L, Olerud J, Johansson M, Hansell P, Palm F. Identification and distribution of uncoupling protein isoforms in the normal and diabetic rat kidney. Adv Exp Med Biol 645: 205-212, 2009.
18. Gill PS, Wilcox CS. NADPH oxidases in the kidney. Antioxid Redox Signal 8: 1597-1607, 2006.
19. Gorin Y, Block K, Hernandez J, Bhandari B, Wagner B, Barnes JL, Abboud HE. Nox4 NAD(P)H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney. J Biol Chem 280: 39616-39626, 2005.
20. Gorin Y, Kim NH, Bsoul S, Feliers D, Zhang JH, Choudhury GG, Abboud H. Induction of hypertrophy by angiotensin II in glomerular mesangial cells via an arachidonic acid-and redox-dependent pathway involving extracellular signal-regulated protein kinase (Abstract). J Am Soc Nephrol 11: 432A, 2000.
21. Griffin KA, Picken M, Bidani AK. Method of renal mass reduction is a critical modulator of subsequent hypertension and glomerular injury. J Am Soc Nephrol 4: 2023-2031, 1994.
22. Grosfeld A, Zilberfarb V, Turban S, Andre J, Guerre-Millo M, Issad T. Hypoxia increases leptin expression in human PAZ6 adipose cells. Diabetologia 45: 527-530, 2002.
23. Hasdan G, Benchetrit S, Rashid G, Green J, Bernheim J, Rathaus M. Endothelial dysfunction and hypertension in 5/6 nephrectomized rats are mediated by vascular superoxide. Kidney Int 61: 586-590, 2002.
24. Hayslett JP, Kashgarian M, Epstein FH. Functional correlates of compensatory renal hypertrophy. J Clin Invest 47: 774-799, 1968.
25. Hobo A, Yuzawa Y, Kosugi T, Kato N, Asai N, Sato W, Maruyama S, Ito Y, Kobori H, Ikematsu S, Nishiyama A, Matsuo S, Kadomatsu K. The growth factor midkine regulates the renin-angiotensin system in mice. J Clin Invest 119: 1616-1625, 2009.
26. Hur W, Gray NS. Small molecule modulators of antioxidant response pathway. Curr Opin Chem Biol 15: 162-173, 2011.
27. Igarashi K, Ueda S, Yoshida K, Kashiwagi K. Polyamines in renal failure. Amino Acids 31: 477-483, 2006.
28. Kawada N, Imai E, Karber A, Welch WJ, Wilcox CS. A mouse model of angiotensin II slow pressor response: role of oxidative stress. J Am Soc Nephrol 13: 2860-2868, 2002.
29. Kim HW, Lin A, Guldberg RE, Ushio-Fukai M, Fukai T. Essential role of extracellular SOD in reparative neovascularization induced by hindlimb ischemia. Circ Res 101: 409-419, 2007.
30. Kim NH, Rincon-Choles H, Bhandari B, Choudhury GG, Abboud HE, Gorin Y. Redox dependence of glomerular epithelial cell hypertrophy in response to glucose. Am J Physiol Renal Physiol 290: F741-F751, 2006.
31. Kitiyakara C, Chabrashvili T, Chen Y, Blau J, Karber A, Aslam S, Welch WJ, Wilcox CS. Salt intake, oxidative stress and renal expression of NADPH oxidase and superoxide dismutase. J Am Soc Nephrol 14: 2775-2782, 2003.
32. Kobayashi N, Hara K, Tojo A, Onozato ML, Honda T, Yoshida K, Mita S, Nakano S, Tsubokou Y, Matsuoka H. Eplerenone shows renoprotective effect by reducing LOX-1-mediated adhesion molecule, PKCepsilon-MAPK-p90RSK, and Rho-kinase pathway. Hypertension 45: 538-544, 2005.
33. Krishna MC, Samuni A, Taira J, Goldstein S, Mitchell JB, Russo A. Stimulation by nitroxides of catalase-like activity of hemeproteins. J Biol Chem 271: 26018-26025, 1996.
34. Kwak MK, Kensler TW, Casero RA Jr. Induction of phase 2 enzymes by serum oxidized polyamines through activation of Nrf2: effect of the polyamine metabolite acrolein. Biochem Biophys Res Commun 305: 662-670, 2003.
35. Lai E, Onozato ML, Solis G, Aslam S, Welch WJ, Wilcox CS. Myogenic responses of mouse isolated perfused renal afferent arterioles: effects of salt intake and reduced renal mass. Hypertension 55: 983-989, 2010.
36. Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM, Mitch WE, Harrison DG. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 111: 1201-1209, 2003.
37. Laycock SK, Vogel T, Forfia PR, Tuzman J, Xu X, Ochoa M, Thompson CI, Nasjletti A, Hintze TH. Role of nitric oxide in the control of renal oxygen consumption and the regulation of chemical work in the kidney. Circ Res 82: 1263-1271, 1998.
38. Li P, Wang D, Onozato M, Welch WJ, Wilcox CS. Tempol attenuates the development of salt-induced hypertension in rats with chronic renal failure (Abstract). J Am Soc Nephrol 19: 376A. 2008.
39. Lu H, Zhen J, Wu T, Peng A, Ye T, Wang T, Yu X, Vaziri ND, Mohan C, Zhou XJ. Superoxide dismutase mimetic drug tempol aggravates anti-GBM antibody-induced glomerulonephritis in mice. Am J Physiol Renal Physiol 299: F445-F452, 2010.
40. Luo Z, Teerlink T, Griendling K, Aslam S, Welch WJ, Wilcox CS. Angiotensin II and NADPH oxidase increase ADMA in vascular smooth muscle cells. Hypertension 56: 498-504, 2010.
41. Lyle AN, Deshpande NN, Taniyama Y, Seidel-Rogol B, Pounkova L, Du P, Papaharalambus C, Lassegue B, Griendling KK. Poldip2, a novel regulator of Nox4 and cytoskeletal integrity in vascular smooth muscle cells. Circ Res 105: 249-259, 2009.
42. Ma LJ, Fogo AB. Model of robust induction of glomerulosclerosis in mice: importance of genetic background. Kidney Int 64: 350-355, 2003.
43. Mailloux RJ, Seifert EL, Bouillaud F, Aguer C, Collins S, Harper ME. Glutathionylation acts as a control switch for uncoupling proteins UCP2 and UCP3. J Biol Chem 286: 21865-21875, 2011.
44. Manotham K, Tanaka T, Matsumoto M, Ohse T, Miyata T, Inagi R, Kurokawa K, Fujita T, Nangaku M. Evidence of tubular hypoxia in the early phase in the remnant kidney model. J Am Soc Nephrol 15: 1277-1288, 2004.
45. Mimura I, Nangaku M. The suffocating kidney: tubulointerstitial hypoxia in end-stage renal disease. Nat Rev Nephrol 6: 667-678, 2010.
46. Modlinger P, Chabrashvili T, Gill PS, Mendonca M, Harrison DG, Griendling KK, Li M, Raggio J, Wellstein A, Chen Y, Welch WJ, Wilcox CS. RNA silencing in vivo reveals role of p22phox in rat angiotensin slow pressor response. Hypertension 47: 238-244, 2006.
47. Muller V, Tain YL, Croker B, Baylis C. Chronic nitric oxide deficiency and progression of kidney disease after renal mass reduction in the C57Bl6 mouse. Am J Nephrol 32: 575-580, 2010.
48. Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol 17: 17-25, 2006.
49. Nath KA, Croatt AJ, Hostetter TH. Oxygen consumption and oxidant stress in surviving nephrons. Am J Physiol Renal Fluid Electrolyte Physiol 258: F1354-F1362, 1990.
50. Onozato ML, Tojo A, Leiper J, Fujita T, Palm F, Wilcox CS. Expression of DDAH and PRMT isoforms in the diabetic rat kidney; effects of angiotensin II receptor blockers. Diabetes 57: 172-180, 2008.
51. Ozeki M, Nagasu H, Satoh M, Namikoshi T, Haruna Y, Tomita N, Sasaki T, Kashihara N. Reactive oxygen species mediate compensatory glomerular hypertrophy in rat uninephrectomized kidney. J Physiol Sci 59: 397-404, 2009.
52. Palm F, Nangaku M, Fasching A, Tanaka T, Nordquist L, Hansell P, Kawakami T, Nishijima F, Fujita T. Uremia induces abnormal oxygen consumption in tubules and aggravates chronic hypoxia of the kidney via oxidative stress. Am J Physiol Renal Physiol 299: F380-F386, 2010.
53. Palm F, Nordquist L. Renal tubulointerstitial hypoxia: cause and consequence of kidney dysfunction. Clin Exp Pharmacol Physiol 38: 424-430, 2011.
54. Pergola PE, Raskin P, Toto RD, Meyer CJ, Huff JW, Grossman EB, Krauth M, Ruiz S, Audhya P, Christ-Schmidt H, Wittes J, Warnock DG. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 365: 327-336, 2011.
55. Quiroz Y, Ferrebuz A, Vaziri ND, Rodriguez-Iturbe B. Effect of chronic antioxidant therapy with superoxide dismutase-mimetic drug, tempol, on progression of renal disease in rats with renal mass reduction. Nephron Exp Nephrol 112: e31-e42, 2009.
56. 2-isoprostanes as an index of oxidative stress in vivo. Free Radic Biol Med 28: 505-513, 2000.
57. Ruta LA, Dickinson H, Thomas MC, Denton KM, Anderson WP, Kett MM. High-salt diet reveals the hypertensive and renal effects of reduced nephron endowment. Am J Physiol Renal Physiol 298: F1384-F1392, 2010.
58. Sahin K, Tuzcu M, Gencoglu H, Dogukan A, Timurkan M, Sahin N, Aslan A, Kucuk O. Epigallocatechin-3-gallate activates Nrf2/HO-1 signaling pathway in cisplatin-induced nephrotoxicity in rats. Life Sci 87: 240-245, 2010.
59. Salehmoghaddam S, Bradley T, Mikhail N, Badie-Dezfooly B, Nord EP, Trizna W, Kheyfets R, Fine LG. Hypertrophy of basolateral Na-K pump activity in the proximal tubule of the remnant kidney. Lab Invest 53: 443-452, 1985.
60. 2_. Hypertension 33: 424-428, 1999.
61. Shin DH, Park HM, Jung KA, Choi HG, Kim JA, Kim DD, Kim SG, Kang KW, Ku SK, Kensler TW, Kwak MK. The NRF2-heme oxygenase-1 system modulates cyclosporin A-induced epithelial-mesenchymal transition and renal fibrosis. Free Radic Biol Med 48: 1051-1063, 2010.
62. Soule BP, Hyodo F, Matsumoto K, Simone NL, Cook JA, Krishna MC, Mitchell JB. The chemistry and biology of nitroxide compounds. Free Radic Biol Med 42: 1632-1650, 2007.
63. 6nephrectomized rat. Am J Physiol Renal Physiol 292: F1404-F1410, 2007.
64. Vaziri ND, Bai YL, Ni Z, Quiroz Y, Pandian R, Rodriguez-Iturbe B. Intra-renal angiotensin II/AT1 receptor, oxidative stress, inflammation and progressive injury in renal mass reduction. J Pharmacol Exp Ther 323: 85-93, 2007.
65. Vaziri ND, Dicus M, Ho ND, Boroujerdi-Rad L, Sindhu RK. Oxidative stress and dysregulation of superoxide dismutase and NADPH oxidase in renal insufficiency. Kidney Int 63: 179-185, 2003.
66. 2and renal oxygen usage in the hypertensive rat kidney. Kidney Int 59: 230-237, 2001.
67. Welch WJ, Blau J, Xie H, Chabrashvili T, Wilcox CS. Angiotensininduced defects in renal oxygenation: role of oxidative stress. Am J Physiol Heart Circ Physiol 288: H22-H28, 2005.
68. Welch WJ, Chabrashvili T, Solis G, Chen Y, Gill P, Aslam S, Wang X, Ji H, Sandberg K, Jose P, Wilcox CS. Role of extracellular superoxide dismutase in the mouse angiotensin slow pressor response. Hypertension 48: 934-941, 2006.
69. 1receptors in renal hemodynamics and oxygenation in the postclipped 2K,1C kidney. Hypertension 41: 692-696, 2003.
70. Wilcox CS. Effects of tempol and redox-cycling nitroxides in models of oxidative stress. Pharmacol Ther 126: 119-145, 2010.
71. Wilcox CS, Pearlman A. Chemistry and antihypertensive effects of tempol and other nitroxides. Pharm Rev 60: 418-469, 2008.
72. Wood PL, Khan MA, Kulow SR, Mahmood SA, Moskal JR. Neurotoxicity of reactive aldehydes: the concept of "aldehyde load" as demonstrated by neuroprotection with hydroxylamines. Brain Res 1095: 190-199, 2006.
73. Zou AP, Li N, Cowley AW. Production and actions of superoxide in the renal medulla. Hypertension 37: 547-553, 2001.